Drug interactions
Dapagliflozin-metformin + Erdafitinib
Severity: Minor
Dapagliflozin-metformin and Erdafitinib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Erdafitinib is an OCT2 substrate, and metformin may compete for or inhibit renal secretion of it. Erdafitinib exposure may rise, increasing the risk of its adverse effects such as hyperphosphatemia, ocular and skin toxicity.
What this interaction means in plain words
Dapagliflozin-metformin and Erdafitinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Dapagliflozin-metformin belongs to Endocrine; Erdafitinib belongs to Oncology.
Why it happens
Metformin may reduce OCT2-mediated renal secretion of erdafitinib, increasing its concentrations.
What to do
Monitor for erdafitinib toxicity, including serum phosphate and eye symptoms, and reduce the erdafitinib dose based on tolerability.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Dapagliflozin-metformin and Erdafitinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Dapagliflozin-metformin
Other interactions of Erdafitinib
Frequently asked questions
Can I take Dapagliflozin-metformin with Erdafitinib?
MediHelp rates the interaction as minor. Dapagliflozin-metformin and Erdafitinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Erdafitinib is an OCT2 substrate, and metformin may compete for or inhibit renal secretion of it. Erdafitinib exposure may rise, increasing the risk of its adverse effects such as hyperphosphatemia, ocular and skin toxicity.
How serious is the interaction between Dapagliflozin-metformin and Erdafitinib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for erdafitinib toxicity, including serum phosphate and eye symptoms, and reduce the erdafitinib dose based on tolerability.
What other medicines interact with Dapagliflozin-metformin?
MediHelp also lists interactions of Dapagliflozin-metformin with, for example, Contrast media, Diatrizoate, Diatrizoate meglumine / diatrizoate. The full list is on the Dapagliflozin-metformin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
